IO Biotech, Inc. — Director's Dealing 2023

Aug 10, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2023-08-09

Reporting Person: Zocca Mai-Britt (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-09	Common Stock	A	37037	$1.9	Acquired	37391	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-09	Warrants (Right to Buy)	$2.47	A	37037	Acquired		Common Stock (37037)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	26580	Indirect

Footnotes

F1: The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of her pecuniary interest therein.

F2: These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023.